Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-17T14:56:59.883Z Has data issue: false hasContentIssue false

Fosphenytoin

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos  and
Erik K. St Louis
Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Epilepsy Prescriber's Guide to Antiepileptic Drugs , pp. 99 - 108
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Aweeka, FT, Gottwald, MD, Gambertoglio, JG, Wright, TL, Boyer, TD, Pollock, AS, Eldon, MA, Kuglar, AR, Alldredge, BK. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40: 777–782.CrossRefGoogle ScholarPubMed
Boucher, BA, Bombassaro, A, Rasmussen, SN, Watridge, CB, Achari, R, Turlapaty, P. Phenytoin prodrug 3-phosphoryloxy-methyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. Journal of Pharmacological Sciences 1989; 78: 923–932.Google Scholar
Eldon, MA, Loewen, GR, Voigtman, RE, Holmes, GB, Hunt, TL, Sedman, AJ. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clinical Pharmacology and Therapeutics 1993; 53: 212.Google Scholar
Leppik, IE, Boucher, BA, Wilder, BJ, Murthy, VS, Watridge, C, Graves, NM, Rask, CA, Turlapaty, P. Pharmacokinetics and safety of a phenytoin prodrug given IV in patients. Neurology 1990; 40: 456–460.CrossRefGoogle ScholarPubMed
Pryor, FM, Gidal, B, Ramsay, RE, DeToledo, J, Morgan, RO. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42: 245–250.Google ScholarPubMed
Thomson, A. Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes. Core Evidence 2005; 1: 65–75.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×